Your browser is no longer supported. Please, upgrade your browser.
Settings
VSTM Verastem, Inc. daily Stock Chart
VSTM [NASD]
Verastem, Inc.
Index- P/E- EPS (ttm)-1.64 Insider Own0.30% Shs Outstand41.90M Perf Week-0.91%
Market Cap137.01M Forward P/E- EPS next Y-1.58 Insider Trans92.90% Shs Float38.80M Perf Month-6.30%
Income-61.20M PEG- EPS next Q-0.43 Inst Own49.60% Short Float3.94% Perf Quarter-9.67%
Sales- P/S- EPS this Y38.80% Inst Trans13.14% Short Ratio1.54 Perf Half Y-1.51%
Book/sh1.09 P/B3.00 EPS next Y9.20% ROA-86.00% Target Price11.80 Perf Year170.25%
Cash/sh1.44 P/C2.27 EPS next 5Y1.74% ROE-110.30% 52W Range1.11 - 5.71 Perf YTD6.51%
Dividend- P/FCF- EPS past 5Y-7.80% ROI- 52W High-42.73% Beta2.19
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low194.59% ATR0.20
Employees32 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)50.06 Volatility4.77% 6.99%
OptionableYes Debt/Eq0.06 EPS Q/Q-187.00% Profit Margin- Rel Volume0.56 Prev Close3.18
ShortableYes LT Debt/Eq0.06 EarningsMar 22 AMC Payout- Avg Volume989.82K Price3.27
Recom2.00 SMA20-2.58% SMA50-0.03% SMA200-4.60% Volume553,347 Change2.83%
Sep-07-17Reiterated H.C. Wainwright Buy $6.50 → $10
Apr-13-17Initiated Oppenheimer Outperform
Mar-24-17Reiterated H.C. Wainwright Buy $5 → $6.50
Sep-29-15Downgrade Raymond James Strong Buy → Outperform
Sep-29-15Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15Downgrade Jefferies Buy → Hold
Sep-29-15Downgrade Cantor Fitzgerald Buy → Hold
Sep-28-15Downgrade ROTH Capital Buy → Neutral $23 → $2
Sep-28-15Downgrade Mizuho Buy → Neutral $21 → $2
Sep-09-15Initiated Raymond James Strong Buy
May-12-15Reiterated UBS Buy $30 → $24
Apr-08-15Initiated H.C. Wainwright Buy $16
Jan-23-15Reiterated ROTH Capital Buy $29 → $23
Jul-08-14Resumed Oppenheimer Perform
Feb-11-14Initiated Mizuho Buy $21
Aug-07-13Reiterated UBS Buy $20 → $30
Jul-12-13Reiterated Oppenheimer Outperform $16 → $18
Jul-09-13Initiated Cantor Fitzgerald Buy $22
Mar-07-12Initiated Oppenheimer Outperform $16
Feb-09-18 07:35AM  Research Report Identifies Ichor, TASER International, Premier, NuVasive, Verastem, and BLACKLINE INC with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:10AM  Blog Exposure - Verastem Reported Submission of NDA For Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL and Follicular Lymphoma ACCESSWIRE
Feb-07-18 08:30AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:00AM  Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma Business Wire
Feb-06-18 04:05PM  Verastem Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jan-26-18 02:45PM  Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell Lymphoma Model Business Wire +5.26%
Jan-04-18 04:01PM  Verastem Announces Increased Hercules Debt Facility Business Wire
07:01AM  Verastem Appoints Joseph Lobacki as Chief Commercial Officer Business Wire
Dec-15-17 09:18AM  Verastem Announces Pricing of Public Offering of Common Stock Business Wire -13.97%
07:00AM  3 Stocks to Watch on Friday: DDR Corp (DDR), Hess Corp. (HES) and Verastem Inc (VSTM) InvestorPlace
Dec-14-17 05:07PM  Verastem Announces Public Offering of Common Stock Business Wire
Dec-12-17 08:20AM  Todays Research Reports on Trending Tickers: Array BioPharma and Verastem, Inc. ACCESSWIRE
Dec-11-17 05:00PM  Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting Business Wire -16.86%
12:07PM  2 Biotech Stocks to Have On Your Radar Into the New Year ACCESSWIRE
07:35AM  Verastem Jumps on Leukemia Drug Study Results Investopedia
Dec-10-17 04:30PM  Verastem Announces Clinical Data from the Pivotal Phase 3 DUO Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Business Wire
Dec-05-17 07:00AM  Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017 Business Wire
Nov-20-17 08:39AM  Options Traders Expect Huge Moves in Verastem (VSTM) Stock Zacks +5.54%
07:55AM  Research Report Identifies Hill-Rom, TASER International, Synchronoss Technologies, NuVasive, Verastem, and Roku with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Nov-08-17 07:00AM  Verastem to Present at Upcoming Investor Conferences Business Wire
Nov-07-17 07:05AM  Verastem reports 3Q loss Associated Press -5.07%
07:00AM  Verastem Reports Third Quarter 2017 Financial Results Business Wire
Nov-02-17 07:30AM  Corporate News Blog - Verastem Announces Plans to Submit NDA Requesting Full Approval of Duvelisib for Treatment of Patients with Relapsed or Refractory CLL/SLL ACCESSWIRE
Nov-01-17 09:25AM  Verastem Announces Data from Phase 3 DUO Study Selected for Oral Presentation at the American Society of Hematology 2017 Annual Meeting Business Wire -9.16%
Oct-31-17 07:00AM  Verastem Announces Regulatory Strategy for Duvelisib New Drug Application Following Guidance from FDA Business Wire
Oct-17-17 07:00AM  Verastem Pays Milestone Payment to Infinity Pharmaceuticals Business Wire
Oct-11-17 04:01PM  Verastem Appoints NgocDiep Le, MD, PhD as Chief Medical Officer Business Wire
Sep-22-17 07:15AM  Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Moleculin Biotech and Verastem ACCESSWIRE
Sep-06-17 11:11AM  Verastem Shares Are Exploding 50% -- Here's Why TheStreet.com +28.13%
10:31AM  Verastem's blood cancer drug succeeds in late-stage trial Reuters
06:15AM  Verastem's blood cancer drug succeeds in late-stage trial Reuters
06:05AM  Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma Business Wire
06:01AM  Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Business Wire
Aug-18-17 09:00AM  Implied Volatility Surging for Verastem (VSTM) Stock Options Zacks
Aug-08-17 04:05PM  Verastem Reports Second Quarter 2017 Financial Results Business Wire
Jul-25-17 07:00AM  Verastem Publishes Scientific Data Highlighting Potential Role of FAK Inhibition in Pancreatic and Breast Cancer Business Wire
Jul-13-17 08:10AM  Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc. Accesswire
Jul-11-17 04:05PM  Verastem Names Julie B. Feder as Chief Financial Officer Business Wire +16.23%
Jul-07-17 08:20AM  Verastem (VSTM) Shows Strength: Stock Adds 42% in Session Zacks
Jun-24-17 10:00AM  Verastem Reports Phase 2 Long-Term Follow-Up Data for Duvelisib in Patients with Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma at the 22nd Congress of the European Hematology Association Business Wire
Jun-07-17 04:05PM  Verastem to Present Long-Term Follow-Up Data from the DYNAMO Study at the 14th International Conference on Malignant Lymphoma Business Wire
Jun-05-17 01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga
May-31-17 07:00AM  Verastem to Present at the Jefferies 2017 Global Healthcare Conference Business Wire -11.97%
May-18-17 06:44AM  Verastem Announces Duvelisib Data Presentations at the 22nd Congress of the European Hematology Association Business Wire
May-11-17 08:00AM  Today's Research Reports on Stocks to Watch: Array Biopharma and Verastem Accesswire
May-10-17 05:18PM  Verastem reports 1Q loss Associated Press +18.45%
04:05PM  Verastem Reports First Quarter 2017 Financial Results Business Wire
09:00AM  BioXcel Therapeutics, Inc. (BTI) Is Launched with Phase 2-ready Programs Addressing Unmet Needs in Immuno-oncology and Neuroscience GlobeNewswire
May-03-17 07:00AM  Verastem Announces Long Term Follow-up Data from the DYNAMO Study Selected for Oral Presentation at the 14th International Conference on Malignant Lymphoma Business Wire
May-02-17 07:00AM  Verastem Appoints Eric K. Rowinsky to the Board of Directors Business Wire
Apr-17-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Ocera Therapeutics and Verastem Accesswire +13.51%
Apr-03-17 07:00AM  Verastem to Present at the 16th Annual Needham Healthcare Conference Business Wire
Apr-02-17 02:05PM  Data on Verastems Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting Business Wire
Mar-29-17 01:04PM  VERASTEM, INC. Financials +7.89%
Mar-24-17 12:51PM  Edited Transcript of VSTM earnings conference call or presentation 23-Mar-17 8:30pm GMT +9.93%
Mar-23-17 04:30PM  Verastem Inc Earnings Call scheduled for 4:30 pm ET today
04:25PM  VERASTEM, INC. Files SEC form 10-K, Annual Report
04:01PM  Verastem Reports Year-End 2016 Financial Results Business Wire
Mar-16-17 07:00AM  Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights Business Wire
Mar-15-17 04:05PM  Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference Business Wire +5.11%
Mar-07-17 07:00AM  Verastem to Present at the 29th Annual ROTH Conference Business Wire
Feb-07-17 07:00AM  Verastem to Present at 19th Annual BIO CEO & Investor Conference Business Wire
Jan-26-17 07:00AM  Verastem Announces Dosing of First Patient in Combination Trial of Defactinib and Avelumab in Patients with Ovarian Cancer Business Wire
Jan-19-17 04:28PM  Verastem Announces Executive Leadership Appointments and Changes Business Wire
12:29PM  Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Jan-11-17 04:34PM  VERASTEM, INC. Files SEC form 8-K/A, Other Events
Jan-09-17 06:00AM  Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan GlobeNewswire
Dec-05-16 09:15PM  Verastem Presents Phase 2 DYNAMO® Clinical Data at ASH 2016 Annual Meeting Business Wire
Nov-11-16 03:06PM  Infinity (INFI) Reports Narrower-than-Expected Loss in Q3
Nov-07-16 05:42PM  Verastem reports 3Q loss
05:00PM  VERASTEM, INC. Files SEC form 10-Q, Quarterly Report
04:05PM  Verastem Reports Third Quarter 2016 Financial Results Business Wire
Nov-03-16 09:13AM  Verastem Announces Presentations at ASH Annual Meeting Business Wire -6.61%
Nov-02-16 07:25AM  VERASTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Dispositi
06:45AM  Verastem Licenses Duvelisib from Infinity Pharmaceuticals PR Newswire
Oct-06-16 07:20PM  HC Wainwright Issues $5 Target for Verastem (VSTM) at Investopedia +7.19%
Sep-30-16 05:00AM  Cancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs Business Wire
Sep-06-16 07:00AM  Verastem to Present at Rodman & Renshaw 18th Annual Global Investment Conference Business Wire
Aug-08-16 09:05AM  VERASTEM, INC. Files SEC form 10-Q, Quarterly Report
08:46AM  Verastem reports 2Q loss
08:40AM  Verastem Reports Second Quarter 2016 Financial Results Business Wire
Jul-06-16 07:00AM  Verastem to Present at Cantor Fitzgeralds 2nd Annual Healthcare Conference Business Wire
Jul-05-16 08:20AM  Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer Business Wire
Jun-14-16 04:12PM  VERASTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
04:05PM  Verastem Announces Changes to its Board of Directors Business Wire
Jun-10-16 05:00PM  Verastem, Inc. :VSTM-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016
Jun-01-16 07:00AM  Verastem to Present at Upcoming Investor Conferences Business Wire
May-16-16 01:03PM  VERASTEM, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-09-16 05:24PM  Verastem reports 1Q loss
05:23PM  VERASTEM, INC. Files SEC form 10-Q, Quarterly Report
04:05PM  Verastem Reports First Quarter 2016 Financial Results Business Wire
May-03-16 09:15AM  Verastem Announces the Presentation of Clinical Data at iMig 2016 Business Wire
Apr-26-16 08:26AM  4 Trending Small Cap Stocks That You Need To Watch Today Accesswire -8.60%
Apr-25-16 08:25AM  8 Breakout Stocks Under $10 to Trade for Big Profits at TheStreet +17.72%
Apr-18-16 05:31PM  VERASTEM, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
05:20PM  Verastem Names Gregory I. Berk, MD as Chief Medical Officer Business Wire
07:00AM  Verastem Co-Founder, Dr. Robert Weinberg, Recognized with Two Prestigious Cancer Research Awards Business Wire
Mar-30-16 04:05PM  Verastem Announces Presentation of Scientific Data Supporting FAK Inhibition in Combination with Immunotherapy at the Keystone Symposium on Cancer Pathophysiology Business Wire
Mar-22-16 04:19PM  Verastem Announces Oral Presentation of Data Supporting the Preferential Targeting of Ovarian Cancer Stem Cells at the Society of Gynecologic Oncologys 2016 Annual Meeting on Womens Cancer at noodls
Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma. The company's duvelisib is in Phase 3 randomized and two-arm trial for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, as well as completed the Phase 2 study for the treatment of patients with refractory indolent non-Hodgkin lymphoma. The company has license agreement with Infinity Pharmaceuticals, Inc.; The Scripps Research Institute; and Pfizer, Inc. Verastem, Inc. was founded in 2010 and is headquartered in Needham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBERICH TIMOTHY JDirectorDec 05Buy3.9560,538239,125130,000Dec 07 04:02 PM
BARBERICH TIMOTHY JDirectorMay 15Buy2.4530,00073,50069,462May 17 08:21 AM